Is Medicus Pharma Ltd. (MDCX) Stock Gaining Momentum With Innovative Skin Cancer Treatment Technology?

TheFly reported connected June 15 that MDCX announced the filing of a Rare Pediatric Disease Designation petition with the U.S. Food and Drug Administration for SkinJect, its investigational doxorubicin-containing microneedle array patch, for the attraction of basal compartment carcinoma successful patients with Gorlin Syndrome.

The submission follows the company's antecedently filed Orphan Drug Designation exertion and ongoing FDA reappraisal of its registrational survey design. MDCX reported that caller Phase 2 results demonstrated encouraging objective and implicit effect rates portion maintaining a favorable information profile. If granted, the designation could enactment the company's regulatory strategy and perchance supply eligibility for a Rare Pediatric Disease Priority Review Voucher, taxable to aboriginal FDA approval.

Separately, Medicus Pharma Ltd. (NASDAQ:MDCX) announced earlier connected June 8 that it had filed a important modification exertion done the European Union CTIS for the planned Phase 2b survey of Teverelix successful precocious prostate cancer. The survey is intended to refine dose enactment portion further evaluating the therapy's pharmacokinetics, pharmacodynamics, efficacy, and information earlier registrational development. The programme is focused connected patients with elevated cardiovascular hazard who necessitate androgen deprivation therapy and builds connected the company's erstwhile regulatory discussions with the FDA regarding its objective improvement strategy for precocious prostate cancer.

Medicus Pharma Ltd. (NASDAQ:MDCX) is simply a biotechnology institution focused connected advancing early-stage therapeutic candidates done objective improvement and partnering with larger pharmaceutical companies for commercialization.

While we admit the imaginable of MDCX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.